Cymetra: a treatment option for refractory ulcers.
Background: CEMETERY is a micronized, injectable form of ALLODERM (LifeCell Corporation, Branchberg, New Jersey), an allogeneic dermal matrix product developed as a filler substance for cosmetic use. Recently, CYMETRA has been reported to be effective in the healing of recalcitrant sinus tracts in t...
| Publicado en: | Wounds: A Compendium of Clinical Research & Practice Vol. 16; no. 12; pp. 359 - 364 |
|---|---|
| Autores principales: | , , , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
HMP Global
2004 Dec Supplement
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106637227&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 106637227 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 10447946 YZM jtl: Wounds: A Compendium of Clinical Research & Practice issn: 10447946 maglogo: N pubinfo: dt: 2004 Dec Supplement vid: 16 iid: 12 pid: 20465 pub: HMP Global place: Malvern, Pennsylvania artinfo: ui: 106637227 106637227 2005084631 106637227 ppf: 359 ppct: 5 formats: tig: atl: Cymetra: a treatment option for refractory ulcers. aug: au: Levy D Banta MR Charles CA Eaglstein WH Kirsner RS affil: Dept of Dermatology and Cutaneous Surgery, University of Miami, Miami, FL sug: subj: Collagen Therapeutic Use Wounds, Chronic Therapy Aged Aged, 80 and Over Collagen Administration and Dosage Female Florida Male Middle Age Record Review Retrospective Design Wound Healing Human Aged: 65+ years Aged, 80 & over Middle Aged: 45-64 years Female Male ab: Background: CEMETERY is a micronized, injectable form of ALLODERM (LifeCell Corporation, Branchberg, New Jersey), an allogeneic dermal matrix product developed as a filler substance for cosmetic use. Recently, CYMETRA has been reported to be effective in the healing of recalcitrant sinus tracts in two patients. Objective: The objective of the authors' study was to evaluate the safety and efficacy of CYMETRA as an adjuvant in the treatment of a variety of chronic wounds. Methods: A retrospective chart review was performed for patients who were treated with CYMETRA at the CURE Wound Care Center at the University of Miami, Miami, Florida. Results: Patients with various types of chronic ulcers, including pyoderma gangrenosum, eosinophilic fasciitis, chronic pressure ulcers, post-operative ulcers, venous insufficiency ulcers, and livedo vasculitis, were treated with CYMETRA injections. All patients had refractory disease and failed to respond to prior treatments, which included APLIGRAF (Organogenesis, Canton, Massachusetts), Dermagraft (Smith & Nephew, Largo, Florida), V.A.C. THERAPY (KCI Inc., San Antonio, Texas), compression, etanercept, mycophenolate mofetil, prednisone, infliximab, cyclosporine, antibiotics, debridement, intralesional triamcinolone acetonide, and granulocyte/macrophage colony-stimulating factor (GMCSF). Of the 13 patients treated with CYMETRA, nine patients' ulcers (69%) healed completely. Conclusions: CYMETRA was well tolerated, and the majority of patients achieved complete healing of their ulcers after treatment. pubtype: Periodical doctype: research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|